Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Mar 16;17(3):e0265498. doi: 10.1371/journal.pone.0265498

Epidemiology of atrial fibrillation in the All of Us Research Program

Alvaro Alonso 1,*, Aniqa B Alam 1, Hooman Kamel 2, Vignesh Subbian 3, Jun Qian 4, Eric Boerwinkle 5, Mine Cicek 6, Cheryl R Clark 7, Elizabeth G Cohn 8, Kelly A Gebo 9, Roxana Loperena-Cortes 10, Kelsey R Mayo 10, Stephen Mockrin 11, Lucila Ohno-Machado 12, Sheri D Schully 13, Andrea H Ramirez 14, Philip Greenland 15
Editor: Gaetano Santulli16
PMCID: PMC8926244  PMID: 35294480

Abstract

Background

The prevalence, incidence and risk factors of atrial fibrillation (AF) in a large, geographically and ethnically diverse cohort in the United States have not been fully described.

Methods

We analyzed data from 173,099 participants of the All of Us Research Program recruited in the period 2017–2019, with 92,318 of them having electronic health records (EHR) data available, and 35,483 having completed a medical history survey. Presence of AF at baseline was identified from self-report and EHR records. Incident AF was obtained from EHR. Demographic, anthropometric and clinical risk factors were obtained from questionnaires, baseline physical measurements and EHR.

Results

At enrollment, mean age was 52 years old (range 18–89). Females and males accounted for 61% and 39% respectively. Non-Hispanic Whites accounted for 67% of participants, with non-Hispanic Blacks, non-Hispanic Asians and Hispanics accounting for 26%, 4% and 3% of participants, respectively. Among 92,318 participants with available EHR data, 3,885 (4.2%) had AF at the time of study enrollment, while the corresponding figure among 35,483 with medical history data was 2,084 (5.9%). During a median follow-up of 16 months, 354 new cases of AF were identified among 88,433 eligible participants. Individuals who were older, male, non-Hispanic white, had higher body mass index, or a prior history of heart failure or coronary heart disease had higher prevalence and incidence of AF.

Conclusion

The epidemiology of AF in the All of Us Research Program is similar to that reported in smaller studies with careful phenotyping, highlighting the value of this new resource for the study of AF and, potentially, other cardiovascular diseases.

Introduction

Atrial fibrillation (AF) is a common cardiac arrhythmia associated with reduced quality of life and increased rates of stroke, heart failure, dementia, and overall mortality [1]. Numerous studies have identified major risk factors for AF, including older age, white race, male sex, hypertension, obesity and other cardiovascular diseases [2]. In the United States, studies on the prevalence, incidence and risk factors of AF have been limited to relatively small but well-phenotyped cohorts [35], or larger administrative or clinical databases restricted to individuals enrolled in geographically-restricted healthcare plans [6], receiving care in selected medical institutions [7], enrolled in specific insurance programs [8], or residing in specific regions of the United States [9]. However, no prior studies have described the epidemiology of AF in a large cohort representing the broad diversity of the US population in terms of ancestry, demographic variables, socioeconomic status, geographic location, and other characteristics.

Launched in 2018, the All of Us Research Program aims to recruit one million participants in the United States with the primary goal of accelerating biomedical research and improving the health of the public [10]. The program obtains data from participants through self-reported surveys, physical measurements, electronic health records (EHRs), and the collection and analysis of biological samples. Over 80% of study participants are from groups that have been traditionally underrepresented in biomedical research [10]. Still, the reliability of the data being collected, particularly in regards to their ability to identify risk factors for disease status, including AF, has not been established yet.

Therefore, our goal was to characterize the epidemiology of AF in the All of Us Research Program to evaluate whether demographic patterns and risk factors of AF established in prior literature replicate in this novel research resource. Replicating these associations would bolster the value of All of Us data for future innovative research on AF and other cardiovascular diseases that takes advantage of the diversity of the study population.

Methods

The All of Us Research Program

The All of Us Research Program is a prospective cohort study aiming to recruit at least one million individuals in the United States, with the overall goal of providing a unique resource to study the effects of lifestyle, environment and genomics on health and health outcomes [10]. Participant recruitment is predominantly done through participating health care provider organizations and in partnership with Federally Qualified Health Centers, with an emphasis on recruiting persons affiliated with those centers. Interested potential participants can also enroll in the program as direct volunteers, visiting community-based enrollment sites. Initial enrollment, informed consent (including consent to share EHRs), and baseline health surveys are done digitally through the All of Us program website (https://joinallofus.org). Once this step is completed, the participant is invited to undergo a basic physical exam and biospecimen collection at the affiliated health care site. Participant follow-up is done in two ways, passively via linkage with EHR and actively by periodic follow-up surveys.

For this study, we included data from participants enrolled in the study between May 2017 and August 2019. This was one of several demonstration projects supported by the All of Us Research Program. Demonstration projects were designed to describe the cohort, replicate previous findings for data validation, and avoid novel discovery in line with the program value to ensure equal access by researchers to the data [11]. The work described here was proposed by Consortium members, reviewed and overseen by the program’s Science Committee, and was confirmed as meeting criteria for non-human subjects research by the All of Us Institutional Review Board. The initial release of data and tools used in this work was published recently [11]. Results reported are in compliance with the All of Us Data and Statistics Dissemination Policy disallowing disclosure of group counts under 20.

The All of Us research hub

This work was performed on data collected by the previously described All of Us Research Program using the All of Us Researcher Workbench, a cloud-based platform where approved researchers can access and analyze All of Us data. All of Us data currently available include surveys, EHR, and physical measurements, with more data and data types slated to be available in future releases. The details of the surveys are available in the Survey Explorer found in the Research Hub, a website designed to support researchers [12]. Each survey includes branching logic and all questions are optional and may be skipped by the participant. Physical measurements recorded at enrollment include systolic and diastolic blood pressure, height, weight, heart rate, waist and hip measurement, wheelchair use, and current pregnancy status. EHR data was linked for those consented participants. All three datatypes (survey, physical measurements, and EHR) are mapped to the Observational Health and Medicines Outcomes Partnership (OMOP) common data model v 5.2 maintained by the Observational Health and Data Sciences Initiative collaborative. To protect participant privacy, a series of data transformations were applied. These included data suppression of codes with a high risk of identification such as military status; generalization of categories, including age, sex at birth, gender identity, sexual orientation, and race; and date shifting by a random (less than one year) number of days, implemented consistently across each participant record. Documentation on privacy implementation and creation of the curated data repository is available in the All of Us Registered Tier CDR Data Dictionary [13]. The Researcher Workbench currently offers tools with a user interface built for selecting groups of participants (Cohort Builder), creating datasets for analysis (Dataset Builder), and Workspaces with Jupyter Notebooks (Notebooks) to analyze data. The Notebooks enable use of saved datasets and direct query using R and Python 3 programming languages.

Sample selection

Among All of Us enrollees, we selected participants 18 to 90 years of age at the time of initial enrollment, who reported either male or female sex at birth, and reported race as white, black or Asian and ethnicity as Hispanic or non-Hispanic.

Characterization of atrial fibrillation

Presence of AF was determined through answers to self-reported questionnaires and from data obtained from EHRs. At enrollment, participants complete a series of online questionnaires. AF was considered to be present if they answered yes to the question “Has a doctor or health care provider ever told you that you have atrial fibrillation?” Participants responding yes to this question were considered to have prevalent AF.

Presence of AF in the EHR was determined if the EHR data contained two or more instances of atrial fibrillation, identified with selected Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) codes. A complete list of SNOMED CT codes and their corresponding OMOP concept IDs is provided in S1 Table. If the EHR-based diagnosis occurred before participant enrollment, AF was considered to be prevalent; otherwise, the diagnosis of AF was considered incident.

Of note, presence or absence of AF was not noted on the physical measurements recorded at enrollment.

Covariates

Date of birth, sex assigned at birth, race, Hispanic ethnicity, and smoking status were self-reported using online surveys. Ever smoking was defined as having smoked over 100 cigarettes over the lifetime. Height and weight were measured by trained study technicians following a standard protocol. Systolic and diastolic blood pressure were measured three times with the participant seated. The mean of the second and third measurement was used for analysis. The following comorbidities were ascertained via self-report in surveys and in the EHR: stroke, heart failure, coronary artery disease, and diabetes.

Statistical analysis

Participant characteristics were summarized by race/ethnicity and by participation in study components (EHR, medical history survey). Prevalence of AF was calculated as the proportion of participants with AF among all participants. We performed separate analyses among individuals participating in the medical history survey and among those whose EHR data were available. For each analysis, we calculated overall prevalence as well as sex, race/ethnicity, and age-specific prevalence. The incidence rates of newly diagnosed AF were calculated as the number of new AF diagnoses after enrollment date divided by person-years of follow-up among those without evidence of AF at enrollment and with EHR data. We calculated incidence of AF overall and by sex, race/ethnicity, and age. Association of risk factors with prevalent AF was evaluated with odds ratios (OR) and 95% confidence intervals (95% CI) from multivariable logistic regression adjusting for age, sex, and race/ethnicity in all models, while associations with incident AF were estimated with hazard ratios (HR) and 95% CI obtained from Cox regression models, also adjusting for age, sex, and race/ethnicity. Time to event was defined as the time in days between baseline and date of incident AF or August 31, 2019, whichever occurred earlier.

Results

Between May 2017 and August 2019, there were 173,099 individuals who enrolled in the All of Us program and met inclusion criteria. Of these individuals, 35,483 (21%) had completed the medical history survey and 92,318 (53%) had EHR data available at the time of dataset creation. There were 20,683 participants who had both medical history survey and EHR data (12% of all eligible individuals). Fig 1 summarizes the flow of participant selection.

Fig 1. Flowchart of study participants, All of Us Research Program, 2017–2019.

Fig 1

EHR: Electronic health records. NHA: Non-Hispanic Asian. NHB: Non-Hispanic Black. NHW: Non-Hispanic White.

Characteristics of study participants by race/ethnicity are presented in Table 1, while characteristics by participation in study components is provided in S2 Table. Approximately two thirds of participants were non-Hispanic Whites, with non-Hispanic Blacks, non-Hispanic Asians and Hispanics accounting for 26%, 4%, and 3% of participants, respectively. Overall mean age (standard deviation) was 52 (17), and females accounted for 61% of all participants. Prevalence of most cardiovascular diseases and risk factors was highest in non-Hispanic Blacks and lowest in non-Hispanic Asians (Table 1). Participants with both EHR and survey data were slightly older, more likely to be female and non-Hispanic White, and had lower prevalence of cardiovascular risk factors (smoking, diabetes) and cardiovascular diseases (stroke, heart failure, coronary heart disease) than those without data from the EHR or the medical history survey (S2 Table). Fig 2 presents the overlap in participants based on availability of EHR and medical history data and diagnosis of AF. In the 20,683 participants with overlapping EHR and survey data, 1,486 had AF either from EHR or medical history survey, with 717 reported in both (48%), 208 in the EHR only (14%), and 561 in the medical survey (38%).

Table 1. Participant characteristics by race/ethnicity.

Values correspond to mean (standard deviation) or N (%), All of Us Research Program, 2017–2019.

Non-Hispanic White Non-Hispanic Black Non-Hispanic Asian Hispanic
N 116,239 (67) 44,993 (26) 7,338 (4) 4,529 (3)
Age, years* 54 (17) 50 (14) 43 (17) 40 (15)
Female sex 72,129 (62) 26,048 (58) 4,428 (60) 2,918 (64)
BMI, kg/m2 28.7 (6.3) 30.3 (7.2) 25.1 (4.7) 29.5 (6.8)
SBP, mmHg 127 (18) 131 (20) 122 (17) 124 (17)
DBP, mmHg 77 (11) 81 (13) 76 (11) 78 (12)
Ever smoker 46,390 (40) 21,280 (47) 1,055 (14) 1,595 (35)
Diabetes 8,773 (7.5) 6,085 (13.5) 381 (5.2) 348 (7.7)
Heart failure 3,034 (2.6) 1,978 (4.4) 74 (1.0) 91 (2.0)
CHD 6,286 (5.4) 2,313 (5.1) 164 (2.2) 149 (3.3)
Stroke 298 (0.3) 175 (0.4) <20 (<0.3) <20 (<0.4)

BMI: body mass index; CHD: coronary heart disease; DBP: diastolic blood pressure; SBP: systolic blood pressure.

* Age range: 18 to 90 years

Fig 2. Venn diagram representing overlap of participants with EHR data, medical history survey data, those with AF in the EHR, and those with self-reported AF in the medical history survey, All of Us Research Program, 2017–2019.

Fig 2

The intersection of these variables leads to eight different groups: (1) among participants with both EHR and medical survey, those with AF in the EHR and the medical survey (n = 717), AF in the medical survey but no in the EHR (n = 561), AF in the EHR but not in the medical survey (n = 208), and no AF in any data source (n = 19,197); (2) among participants with EHR but not medical survey, AF in the EHR (n = 3,314) and no AF (n = 68,322); and (3) among participants with medical history survey but not EHR, AF in the medical survey (n = 806) and no AF (n = 13,994). The diagram does not include 65,982 participants with neither EHR nor medical history survey.

Among eligible All of Us participants, 35,483 provided data on prior history of medical conditions, including AF. Of them, 2,084 (5.9%) reported a diagnosis of AF. Prevalence of self-reported AF by age group, race/ethnicity and sex are reported in Table 2. Prevalence increased with age, from <1% among participants younger than 40 to >20% in those 80 and older. Males and non-Hispanic Whites reported higher prevalence than females and other racial/ethnic groups. These differences persisted after simultaneous adjustment for age, sex and race/ethnicity, with men having approximately 70% higher odds of AF than females (OR 1.7, 95% CI 1.5, 1.8), and groups other than non-Hispanic Whites having 25–43% lower odds of self-reported AF than non-Hispanic Whites. The associations were similar when the analysis was restricted to the 20,683 participants who completed the medical history survey and had available EHR data (S3 Table).

Table 2. Prevalence of self-reported atrial fibrillation (AF) by age, sex, and race/ethnicity, All of Us Research Program, 2017–2019.

Age group AF cases Total AF prevalence (%) Odds ratio (95% CI)*
    <40 80 8,673 0.9 1 (Ref.)
    40–49 91 4,213 2.2 2.3 (1.7, 3.2)
    50–59 235 6,416 3.7 4.0 (3.1, 5.1)
    60–69 686 9,193 7.5 7.9 (6.3, 10.0)
    70–79 781 6,029 13.0 13.8 (11.0, 17.5)
    80–89 211 959 22.0 25.8 (19.7, 33.9)
Sex
    Female 1,014 23,326 4.3 1 (Ref.)
    Male 1,070 12,157 8.8 1.7 (1.5, 1.8)
Race / ethnicity
    Hispanic <20 743 <2.7 0.75 (0.47, 1.2)
    NH Asian 27 1,295 2.1 0.57 (0.38, 0.84)
    NH Black 63 2,239 2.8 0.61 (0.47, 0.79)
    NH White 1,976 31,206 6.3 1 (Ref.)

* Results from binary logistic regression including age category, sex and race as independent variables in the same model.

A similar pattern was observed among 92,318 All of Us participants with linked EHR. A total of 3,885 (4.2%) participants had evidence of prevalent AF in their EHR at the time of enrollment. During a median follow-up of 16 months, an additional 354 (0.4%) participants were diagnosed with AF after enrollment. Age, sex, and race/ethnicity-specific prevalence and incidence of AF are shown in Table 3. Older age was strongly associated with higher prevalence of AF. For example, compared to those younger than 40, the OR of prevalent AF among those 80 and older was 66.2 (95% CI 51.5, 85.1). Males had 90% higher odds of prevalent AF than females (OR 1.9, 95% CI 1.8, 2.0), while odds of prevalent AF were lower in all race/ethnicity groups compared to non-Hispanic Whites. Similarly, older age and male sex were also associated with higher rates of incident AF. Compared to non-Hispanic Whites, both non-Hispanic Asians and non-Hispanic Blacks experienced lower rates of AF (HR 0.41, 95% CI 0.15, 1.1, and HR 0.55, 95% CI 0.40, 0.76, respectively). Rates of AF in Hispanics were higher than in non-Hispanic Whites, but this is based on a small number of AF events (<20).

Table 3. Prevalence and incidence of EHR-derived AF by age, sex, and race/ethnicity, All of Us Research Program, 2017–2019.

Prevalent AF Incident AF
Age group AF cases Total Prevalence (%) Odds Ratio (95% CI)* AF cases Person-years Incidence** Hazard Ratio (95% CI)***
    <40 71 23,285 0.3 1 (Ref.) <20 32,271 <0.6 1 (Ref.)
    40–49 160 12,609 1.3 4.2 (3.2, 5.6) <20 17,006 <1.2 2.9 (1.4, 5.9)
    50–59 466 19,326 2.4 8.0 (6.2, 10.3) 57 25,830 2.2 6.0 (3.2, 11.2)
    60–69 1150 21,016 5.5 17.8 (14.0, 22.6) 110 26,893 4.1 10.4 (5.7, 19.0)
    70–79 1445 12,979 11.1 35.8 (28.1, 45.5) 116 15,314 7.6 17.4 (9.6, 31.7)
    80–89 593 3,103 19.1 66.2 (51.5, 85.1) 41 3,232 12.3 28.1 (14.7, 53.7)
Sex
    Female 1,751 57,439 3.0 1 (Ref.) 170 76,083 2.2 1 (Ref.)
    Male 2,134 34,879 6.1 1.9 (1.8, 2.0) 184 44,464 4.1 1.7 (1.4, 2.1)
Race / ethnicity
    Hispanic 46 2,496 1.8 0.89 (0.66, 1.2) <20 3,372 <5.9 1.4 (0.71, 2.9)
    NH Asian 62 3,444 1.8 0.63 (0.49, 0.82) <20 4,850 <4.1 0.41 (0.15, 1.1)
    NH Black 544 24,435 2.2 0.64 (0.58, 0.71) 48 31,102 1.5 0.55 (0.40, 0.76)
    NH White 3,233 61,943 5.2 1 (Ref.) 294 81,222 3.6 1 (Ref.)

* Results from binary logistic regression including age category, sex and race as independent variables in the same model.

** Per 1,000 person-years.

*** Results from Cox regression including age category, sex and race as independent variables in the same model.

Table 4 shows the association of selected cardiovascular risk factors and cardiovascular diseases with prevalent and incident AF among participants with EHR data. Higher BMI and prior history of heart failure or coronary heart disease were associated with increased prevalence and incidence of AF. Diabetes and stroke history were associated with prevalent AF but not incident AF. Finally, neither blood pressure nor smoking status were risk factors for AF in this population. The pattern of associations was comparable among the 20,683 participants who completed the medical history survey and had available EHR data (S3 Table).

Table 4. Multivariable model for prevalent and incident AF (odds ratio or hazard ratio for covariates), All of Us Research Program 2017–2019.

Prevalent AF Incident AF
Odds ratio (95% CI)* Hazard ratio (95% CI)**
BMI, per 5 kg/m2 1.1 (1.1, 1.2) 1.2 (1.1, 1.3)
SBP, per 20 mmHg 0.78 (0.74, 0.82) 0.98 (0.84, 1.1)
DBP, per 10 mmHg 1.1 (1.1, 1.20) 1.0 (0.93, 1.2)
Ever smoking 0.93 (0.86, 1.0) 1.1 (0.86, 1.3)
Diabetes 1.2 (1.1, 1.3) 1.0 (0.77, 1.3)
Heart failure 6.6 (6.0, 7.2) 3.4 (2.5, 4.7)
Coronary heart disease 2.7 (2.5, 2.9) 1.6 (1.2, 2.1)
Stroke 2.9 (2.2, 3.8) 1.2 (0.39, 3.8)

* Binary logistic regression adjusted for age, sex, race/ethnicity and all the variables included in the table.

** Cox regression adjusted for age, sex, race/ethnicity and all the variables included in the table.

Discussion

Our analysis describes the epidemiologic characteristics of AF among the diverse participants in the All of Us Research Program. The main findings were that both prevalence and incidence of AF increased with age, were higher in males than females, and non-Hispanic Whites than in other racial/ethnic groups. These patterns are comparable to those from other epidemiologic studies in the US (S4 and S5 Tables). Previously described risk factors for AF, including obesity, diabetes, and prevalence of some cardiovascular diseases, were associated with the risk of AF. The overall findings from this analysis are consistent with established observations about the epidemiology of AF.

Over the last two decades, seminal studies in the epidemiology of AF conducted in community-based cohort studies have demonstrated that older age, male sex and being non-Hispanic White are strongly associated with a higher prevalence and incidence of AF [36]. These same studies have also contributed to identify the major risk factors for AF, including hypertension, obesity, and prior history of other cardiovascular diseases [3, 14].

Analyses of administrative databases, such as Medicare, have complemented findings from traditional cohort studies on the epidemiology of AF, offsetting their limitations in validity of disease and risk factor phenotyping by their large sample size and broader geographic distribution [8, 9]. In the United States, however, these administrative databases are limited to certain age groups (Medicare beneficiaries older than 65), individuals from specific socioeconomic strata (Medicaid beneficiaries), types of healthcare facilities, or geographic area (state-based databases). Nonetheless, their findings are consistent with those of traditional cohort studies [35, 14].

In comparison with other studies, the All of Us Research Program provides a unique opportunity to characterize the epidemiology and risk factors of common chronic conditions, including AF, in a large and extremely diverse population. Given its specific focus on recruiting groups previously underrepresented in biomedical research, findings from All of Us have the potential of being more generalizable to the overall population. In this context, our analysis has replicated previously described aspects of the epidemiology of AF. As the All of Us Research Program develops and other types of data become available, including genomic information, the rich demographic and geographic diversity among participants will enhance research among underrepresented groups. For example, the most recent published genome-wide association study of AF included less than 9,000 Blacks, of which 1,307 had AF, and approximately 3,000 Hispanics (277 AF cases) [15]. The All of Us Research Program will eventually provide data orders of magnitude larger, making possible to understand the influence of ancestry on AF risk and the impact that socioeconomic adversity, disproportionally affecting some underrepresented groups, has on AF risk and outcomes [16, 17].

Most of the explored associations were consistent with previous literature. Older age, male sex and non-Hispanic white race, prevalent diabetes, a prior history of cardiovascular disease (heart failure, stroke, coronary artery disease), as well as higher body mass index, were all associated with higher risk of AF. Most of these risk factors are part of established scores for the prediction of AF [14]. However, elevated systolic blood pressure, which is a consistently described risk factor for AF, was not associated with higher AF risk in the All of Us sample. This may be due to not accounting for the use of antihypertensive medication.

We draw two major conclusions from these results. First, by observing the expected associations of demographic and clinical factors with the risk of AF, we are indirectly supporting the validity of the All of Us Research Program data for future studies on the epidemiology of AF and its outcomes. Second, our findings provide additional evidence suggesting that AF rates are highest among non-Hispanic Whites. Ancestry-related genetic factors seem to be partly responsible for this, as shown by higher risk of AF associated with increased degrees of European ancestry among African Americans [18]. Though a few reports suggest that under-ascertainment among non-Whites could partially explain these differences [19], most studies using extended electrocardiographic recordings or pacemaker data and, therefore, less likely to have biased ascertainment, confirm these racial/ethnic differences [2023].

Our analysis has some major strengths, including the large sample size and the racial/ethnic diversity of the study population. Absence of validated AF diagnoses, lack of AF ascertainment at the time of enrollment physical measurements, and missing EHR or medical survey data in large subsets of the study population can be considered major weaknesses. Previous studies, however, have demonstrated the validity of administrative diagnostic data to identify AF diagnoses [24]. Also, using medical history or EHR data resulted in comparable patterns of AF prevalence by age, sex and race/ethnicity, indicating that both sources of information may offer valid data.

In conclusion, in a novel research resource such as the All of Us Research Program, we identified epidemiologic patterns of AF similar to what studies with different designs and methods have reported. These findings provide indirect evidence of the validity of data collected by the All of Us Research Program and support the value of this resource to conduct studies on the epidemiology of AF and, potentially, other cardiovascular diseases.

Supporting information

S1 Table. Concept IDs used to identify atrial fibrillation in the electronic health records, All of Us Research Program, 2017–2019.

(DOCX)

S2 Table. Participant characteristics by study component participation.

Values correspond to mean (standard deviation) or N (%), All of Us Research Program 2017–2019.

(DOCX)

S3 Table. Association of age, sex, race/ethnicity and cardiovascular risk factors with prevalent atrial fibrillation among All of Us participants with EHR and medical history survey data (N = 20,683), All of Us Research Program, 2017–2019.

(DOCX)

S4 Table. Age, sex, and race/ethnicity prevalence of AF in the All of Us Research Program and selected epidemiologic studies in the United States.

Values correspond to prevalence per 100 persons.

(DOCX)

S5 Table. Age, sex, and race/ethnicity incidence rates of AF in the All of Us Research Program and selected epidemiologic studies in the United States.

Values correspond to incidence rate per 1000 person-years.

(DOCX)

Acknowledgments

The All of Us Research Program would not be possible without the partnership of its participants. We are also grateful by the contributions of All of Us Research Program investigators. Dr. Gebo initiated this work while serving as Chief Medical and Scientific Officer of the All of Us Research Program.

Data Availability

Data used for this manuscript is obtained from the All of Us Research Program and not owned by the authors. Data from the All of Us Research Program is accessible only through the Researcher Workbench (https://workbench.researchallofus.org) as stipulated in the informed consent of participants in the program. This data use agreement prohibits investigators from providing row level data on AllofUs participants and thus providing a de-identified dataset is not possible for this manuscript. The code used for this demonstration project is available within the Researcher Workbench at https://workbench.researchallofus.org/workspaces/aou-rw-23896673/afibepidemiologyaouv4/notebooks/preview/Basic.ipynb. Any investigator interested in accessing data used for this manuscript or any other All of Us Research Program data can do so following the procedures outlined in https://www.researchallofus.org/apply/.

Funding Statement

The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. Research reported in this publication was also supported by the American Heart Association award 16EIA26410001 and the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number K24HL148521. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120(9):1501–17. doi: 10.1161/CIRCRESAHA.117.309732 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics—2021 Update: a report from the American Heart Association. Circulation. 2021;143(8):e254–e743. doi: 10.1161/CIR.0000000000000950 [DOI] [PubMed] [Google Scholar]
  • 3.Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–4. [PubMed] [Google Scholar]
  • 4.Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158(1):111–7. doi: 10.1016/j.ahj.2009.05.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455–61. doi: 10.1161/01.cir.96.7.2455 [DOI] [PubMed] [Google Scholar]
  • 6.Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370–5. doi: 10.1001/jama.285.18.2370 [DOI] [PubMed] [Google Scholar]
  • 7.Chamberlain AM, Gersh BJ, Alonso A, Chen LY, Berardi C, Manemann SM, et al. Decade-long trends in atrial fibrillation incidence and survival: a community study. Am J Med. 2015;128(3):260–7. doi: 10.1016/j.amjmed.2014.10.030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries: 1993–2007. Circ Cardiovasc Qual Outcomes. 2012;5(1):85–93. doi: 10.1161/CIRCOUTCOMES.111.962688 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident atrial fibrillation among Asians, Hispanics, blacks and whites. Circulation. 2013;128(23):2470–7. doi: 10.1161/CIRCULATIONAHA.113.002449 [DOI] [PubMed] [Google Scholar]
  • 10.Denny JC, Rutter JL, Goldstein DB, Philippakis A, Smoller JW, Jenkins G, et al. The "All of Us" Research Program. N Engl J Med. 2019;381(7):668–76. doi: 10.1056/NEJMsr1809937 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ramirez AH, Sulieman L, Schlueter DJ, Halvorson A, Qian J, Ratsimbazafy F, et al. The All of Us Research Program: data quality, utility, and diversity. medRxiv. 2020; 10.1101/2020.05.29.20116905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.All of Us Research Hub [Available from: https://www.researchallofus.org/.
  • 13.Data Methodology–All of Us Research Hub [Available from: https://www.researchallofus.org/data-tools/methods/.
  • 14.Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF Consortium. J Am Heart Assoc. 2013;2(2):e000102. doi: 10.1161/JAHA.112.000102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Roselli C, Chaffin MD, Weng L-C, Aeschbacher S, Ahlberg G, Albert CM, et al. Multi-ethnic genome-wide association study for atrial fibrillation. Nat Genet. 2018;50(9):1225–33. doi: 10.1038/s41588-018-0133-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Soliman EZ, Alonso A, Goff DC Jr. Atrial fibrillation and ethnicity: the known, the unknown and the paradox. Future Cardiol. 2009;5(6):547–56. doi: 10.2217/fca.09.49 [DOI] [PubMed] [Google Scholar]
  • 17.Amponsah MKD, Benjamin EJ, Magnani JW. Atrial fibrillation and race—a contemporary review. Curr Cardiovasc Risk Rep. 2013;7:336–45. doi: 10.1007/s12170-013-0327-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Marcus GM, Alonso A, Peralta CA, Lettre G, Vittinghoff E, Lubitz SA, et al. European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation. 2010;122(20):2009–15. doi: 10.1161/CIRCULATIONAHA.110.958306 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Heckbert SR, Austin TR, Jensen PN, Chen LY, Post WS, Floyd JS, et al. Differences by race/ethnicity in the prevalence of clinically detected and monitor-detected atrial fibrillation: MESA. Circ Arrhythm Electrophysiol. 2020;13(1):e007698. doi: 10.1161/CIRCEP.119.007698 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Loehr LR, Soliman EZ, Poon AK, Couper D, Chen LY, Mosley TH, et al. The prevalence of atrial fibrillation on 48-hour ambulatory electrocardiography in African Americans compared to Whites: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2019;216:1–8. doi: 10.1016/j.ahj.2019.06.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Kamel H, Kleindorfer DO, Bhave PD, Cushman M, Levitan EB, Howard G, et al. Rates of atrial fibrillation in black versus white patients with pacemakers. J Am Heart Assoc. 2016;5(2). doi: 10.1161/JAHA.115.002492 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Lau CP, Gbadebo TD, Connolly SJ, Van Gelder IC, Capucci A, Gold MR, et al. Ethnic differences in atrial fibrillation identified using implanted cardiac devices. J Cardiovasc Electrophysiol. 2013;24(4):381–7. doi: 10.1111/jce.12066 [DOI] [PubMed] [Google Scholar]
  • 23.Rooney MR, Soliman EZ, Lutsey PL, Norby FL, Loehr LR, Mosley TH, et al. Prevalence and characteristics of subclinical atrial fibrillation in a community-dwelling elderly population: The ARIC Study. Circ Arrhythm Electrophysiol. 2019;12(10):e007390. doi: 10.1161/CIRCEP.119.007390 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:141–7. doi: 10.1002/pds.2317 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Gaetano Santulli

13 Dec 2021

PONE-D-21-37941Epidemiology of atrial fibrillation in the All of Us Research ProgramPLOS ONE

Dear Dr. Alonso,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 27 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Prof. Gaetano Santulli, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This study proposes to establish the prevalence, incidence, and risk factors for atrial fibrillation in a large cohort.

Among 92,318 participants with available EHR data, 3,885 (4.2%) had AF at the time of study enrolment. During a median follow-up of 16 months, 354 new cases of AF were identified among 88,433 eligible participants.

This study confirms information already known, but remains interesting. Its main problem concerns recruitment bias and the reliability of the information collected. Indeed, AF was not noted on the physical measurements recorded at enrollment. This would have avoided some false positives and false negatives. Indeed, the way AF is diagnosed, either at enrolment or in the follow-up, inevitably leads to diagnostic errors.

Major concern

1/ You need to be clearer about the number of patients evaluated, throughout the paper.

For example, 35,483 (21%) had completed the medical history survey and 92,318 (53%) had EHR data available at the time of dataset creation. There were 20,683 participants who had both medical history survey and EHR data. So your data is from how many unique patients actually? 107,118 ?

2/ Can you detail the number of 50,822 excluded patients for not meeting inclusion criteria ? This seems like a high number when you start with 223,921 patients. How many because of age? gender? race?

3/ The result on blood pressure is very surprising. It needs to be better explained in the discussion.

Minor concerns

1/ Figure 1 should be reworked according to the usual presentation of a flow chart.

2/ I don't understand why you give the total population statistics in table 1, when you have usable data for only a portion of them in the rest of the study.

Reviewer #2: The manuscript aimed to investigate the prevalence, incidence and risk factors of atrial fibrillation in a large, geographically and ethnically diverse cohort in the United States.

The idea is interesting with few elements of novelty. The sample size is adequate but the study suffers from a lack of iconography and the statistical analysis is poor. The discussion and the reference section needs to be improved. Please cite and discuss the role of comorbidities in atrial fibrillation:

- 34793855

- 28450367

- 34440883

- 33238738

- 34101155

- 30926014

- 32495723

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Gaetano Santulli

3 Mar 2022

Epidemiology of atrial fibrillation in the All of Us Research Program

PONE-D-21-37941R1

Dear Dr. Alonso,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Gaetano Santulli, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Gaetano Santulli

7 Mar 2022

PONE-D-21-37941R1

Epidemiology of atrial fibrillation in the All of Us Research Program

Dear Dr. Alonso:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Gaetano Santulli

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Concept IDs used to identify atrial fibrillation in the electronic health records, All of Us Research Program, 2017–2019.

    (DOCX)

    S2 Table. Participant characteristics by study component participation.

    Values correspond to mean (standard deviation) or N (%), All of Us Research Program 2017–2019.

    (DOCX)

    S3 Table. Association of age, sex, race/ethnicity and cardiovascular risk factors with prevalent atrial fibrillation among All of Us participants with EHR and medical history survey data (N = 20,683), All of Us Research Program, 2017–2019.

    (DOCX)

    S4 Table. Age, sex, and race/ethnicity prevalence of AF in the All of Us Research Program and selected epidemiologic studies in the United States.

    Values correspond to prevalence per 100 persons.

    (DOCX)

    S5 Table. Age, sex, and race/ethnicity incidence rates of AF in the All of Us Research Program and selected epidemiologic studies in the United States.

    Values correspond to incidence rate per 1000 person-years.

    (DOCX)

    Attachment

    Submitted filename: response to reviewers.docx

    Data Availability Statement

    Data used for this manuscript is obtained from the All of Us Research Program and not owned by the authors. Data from the All of Us Research Program is accessible only through the Researcher Workbench (https://workbench.researchallofus.org) as stipulated in the informed consent of participants in the program. This data use agreement prohibits investigators from providing row level data on AllofUs participants and thus providing a de-identified dataset is not possible for this manuscript. The code used for this demonstration project is available within the Researcher Workbench at https://workbench.researchallofus.org/workspaces/aou-rw-23896673/afibepidemiologyaouv4/notebooks/preview/Basic.ipynb. Any investigator interested in accessing data used for this manuscript or any other All of Us Research Program data can do so following the procedures outlined in https://www.researchallofus.org/apply/.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES